Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Gregory J. Herrema sold 33,327 shares of Thermo Fisher Scientific stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $219.70, for a total value of $7,321,941.90. Following the completion of the sale, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at $198.73 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $79,270.00, a PE ratio of 35.49, a P/E/G ratio of 1.53 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 12-month low of $151.74 and a 12-month high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.66 by $0.13. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. Thermo Fisher Scientific’s quarterly revenue was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.41 earnings per share. research analysts expect that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be given a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.34%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s payout ratio is currently 10.71%.

Several analysts have issued reports on TMO shares. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research note on Tuesday, October 31st. Leerink Swann reissued an “outperform” rating and issued a $200.00 price target (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Evercore ISI started coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price target on the stock. Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. Finally, BTIG Research started coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $220.50.

Several large investors have recently added to or reduced their stakes in TMO. Bank of Nova Scotia Trust Co. acquired a new position in Thermo Fisher Scientific during the third quarter worth approximately $106,000. Keeler Thomas Management LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $106,000. Ropes Wealth Advisors LLC increased its position in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 97 shares during the last quarter. Atlantic Trust LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth approximately $138,000. Finally, Acrospire Investment Management LLC increased its position in Thermo Fisher Scientific by 66.7% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock worth $174,000 after buying an additional 400 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Thermo Fisher Scientific Inc. (TMO) SVP Sells 33,327 Shares of Stock” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/09/insider-selling-thermo-fisher-scientific-inc-tmo-svp-sells-33327-shares-of-stock.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.